We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Tests for Chagas Disease Improves Diagnostic Access

By LabMedica International staff writers
Posted on 08 Jul 2025

Chagas disease, caused by the parasite Trypanosoma cruzi, affects between six and seven million people across the Americas. More...

It is primarily transmitted by insect vectors and remains largely underdiagnosed, with less than 1% of those infected receiving treatment. The disease is most commonly diagnosed through serological techniques, which detect antibodies to T. cruzi in the blood during the chronic phase of the disease. However, these methods require specialized personnel and equipment, which are often unavailable in resource-limited areas, making it difficult for people in endemic regions to access proper diagnosis and care. A new approach, combining rapid diagnostic tests (RDTs) with conventional serological techniques, has been proposed to improve access to diagnosis in such settings.

Researchers at the Barcelona Institute for Global Health (ISGlobal, Barcelona, Spain), in collaboration with Paraguayan health authorities, conducted a study involving a screening campaign in an indigenous community in the Paraguayan Chaco, where 999 people were tested. The researchers evaluated the effectiveness of using RDTs for initial screening, followed by confirmation with conventional serological tests such as recombinant and lysate ELISA. The combination of these two methods was found to be highly effective, providing an accessible and rapid solution for diagnosing Chagas disease in remote areas.

The study, published in PLOS Neglected Tropical Diseases, demonstrated that the algorithm using RDTs showed high agreement with the standard algorithm, with a sensitivity of 94.6% and a specificity of 98.6%. The algorithm validated in the study suggests using RDTs for an initial screening of at-risk individuals in endemic areas, thereby reducing the need for serological testing to confirm positive results. The prevalence of the disease was found to be significantly higher in the indigenous community of Casanillo compared to the capital, Asunción, highlighting the health inequalities in urban and rural areas. The researchers plan to further evaluate this approach in other regions and adapt it for broader use in endemic areas to improve access to diagnosis and treatment.

“The results obtained are particularly relevant in the context of a global re-evaluation of guidelines for the diagnosis and treatment of Chagas disease,” said Irene Losada, coordinator of the Chagas Initiative at ISGlobal and senior author of the study. “The adoption of RDT-based algorithms adapted to each region could improve access to diagnosis for thousands of people in remote areas.”

Related Links:
ISGlobal


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.